Unlearn.ai: Accelerating Clinical Trials with AI-Powered Digital Twins

Unlearn.ai is an AI platform designed to revolutionize clinical research by leveraging digital twins of patients to optimize trial design and accelerate timelines. Built on disease-specific machine learning models trained on historical clinical data, the platform enables precise predictions of clinical outcomes, reduces control arm sizes, and speeds up decision-making across therapeutic areas like neuroscience, immunology, and metabolic diseases. Used by leading biopharma companies such as AbbVie and Trace Neuroscience, Unlearn.ai supports regulatory acceptance from the FDA and EMA and is transforming medicine into a computational science. The Unlearn Platform includes Evidence and Digital Twin Generators, offering flexible engagement models for full-service or custom infrastructure solutions.

Key Features:

• Digital Twin Generators (DTGs): Creates patient-specific digital twins using machine learning models for accurate clinical outcome predictions.
• Clinical Trial Optimization: Reduces sample size, increases statistical power, and accelerates trial timelines.
• Regulatory-Ready: Recognized and supported by U.S. FDA and European Medicines Agency for use in Phase 2/3 trials.
• Disease-Specific Models: Trained on over 1 million clinical study records across 20+ therapeutic indications.
• Evidence Generation: Provides robust evidence for trial design and regulatory submissions.
• Therapeutic Area Expertise: Focuses on neuroscience, immunology, metabolic disease, and other complex conditions.
• Flexible Engagement: Offers full-service and custom infrastructure models for pharma and biotech partners.
• Scientific Validation: Supported by publications in journals like The Journal of the Alzheimer's Association and arXiv.

Pricing: Unlearn.ai offers a freemium model with flexible engagement options, including full-service and custom infrastructure solutions.

Conclusion: Unlearn.ai is a pioneering AI platform that is transforming clinical research by making precision medicine more accessible and efficient, with strong support from leading pharmaceutical companies and regulatory bodies.